ARCT Stock Analysis: Buy, Sell, or Hold?
ARCT - Arcturus Therapeutics Holdings Inc. Common Stock
$7.32
-0.05 (-0.68%)
▼
5d:
-1.88%
30d:
+17.12%
90d:
-26.58%
BUY
HIGH Confidence
Last Updated: February 3, 2026
Earnings: Mar 05, 2026
28d
Get Alerted When ARCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ARCT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ARCT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ARCT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: ARCT is currently trading at $7.32, which is considered fair relative to its 30-day fair value range of $6.57 to $7.61.
Technical Outlook: Technically, ARCT is in a strong downtrend. Immediate support is located at $7.00, while resistance sits at $7.95.
Market Sentiment: ARCT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.56 (+358.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARCT is in a strong downtrend. Immediate support is located at $7.00, while resistance sits at $7.95.
Market Sentiment: ARCT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.56 (+358.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$6.57 -
$7.61
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 358.4% below Wall St target ($33.56)
Fair Price Analysis
30-Day Fair Range
$6.57 -
$7.61
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.73
(10.0%)
Support & Resistance Levels
Support Level
$7.00
Resistance Level
$7.95
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.75
Wall Street Target
$33.56
(+358.4%)
Revenue Growth (YoY)
-58.8%
Profit Margin
-68.3%
Last updated: February 04, 2026 9:34 AM ET
Data refreshes hourly during market hours. Next update: 10:34 AM
Data refreshes hourly during market hours. Next update: 10:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 59 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$71 | 62 BUY |
|
ALLO
Allogene Therapeutics Inc |
STRONG BUY
14 analysts |
$7 | 62 BUY |
